SSY Group (HKG:2005) has obtained drug production and registration approval for its phenylephrine hydrochloride injection from China's National Medical Products Administration, a Tuesday bourse filing said.

The approval came as the drug passed the regulator's consistency evaluation.

The drug is mainly used to maintain blood pressure during anesthesia and treatment of shock, as well as to control paroxysmal supraventricular tachycardia.

Shares of the pharmaceutical company were up nearly 3% in recent trade.